HelixBind, which is developing an innovative diagnostic platform funded by CARB-X to test for drug-resistant bacterial infections, has been awarded a new $3-million grant from the US National Institutes of Health (NIH). The NIH grant is to support the expansion of capabilities of RaPID, its direct-from-blood platform for the identification and characterization of bloodstream infections, to test for fungal infections. The new test would utilize the same analyzer and cassette as the RaPID diagnostic for drug resistant bacteria, but would use a separate panel to diagnose fungal infections, particularly Candida auris, an emerging fungus resistant to existing antifungals. HelixBind’s diagnostic platform aims to reduce time-to-diagnosis of bloodstream infections from days to hours.